IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

STIEKEMA ET AL.

Serial No.: To be assigned

Group Art Unit: To be assigned

Filed: November 2, 2001

Examiner: To be assigned

For: USE OF OLIGOSACCHARIDE FOR PREVENTING BLOOD CLOTTING IN

EXTRACORPOREAL BLOOD CIRCUITS

Divisional of: USSN 09/424,626, filed November 24, 1999

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents Washington, D.C. 20231

November 2, 2001

Sir:

Prior to examination of this divisional application, please cancel claims 2-10, and add new claims 11-18.

IN THE SPECIFICATION:

Please replace page 1 with new page 1 and add new page 8 with the Abstract of the Disclosure as follows:

USE OF OLIGOSACCHARIDE FOR PREVENTING BLOOD CLOTTING IN EXTRACORPOREAL BLOOD CIRCUITS

This application is a divisional application of USSN 09/424,626 filed November 24, 1999, now pending.

The invention relates to the use of a certain oligosaccharide for the manufacture of a medicament for preventing blood clotting in extracorporeal blood circuits. Further the invention relates to a pharmeuceutical composition for said use.

Blood clotting in extracorporeal blood circuits needs to be prevented. Otherwise, blood coagulation occurs as soon as blood contacts artificial surfaces. As a remedy, usually unfractionated heparin (UFH) or low molecular weight heparins (LMWH) are used as anticoagulants.

Both UFH and LMWH have an effect on several stages of the blood coagulation cascade, both inhibiting factor Xa and thrombin (factor IIa). Factor Xa catalyzes the generation of thrombin and subsequently thrombin regulates the last step in the coagulation cascade. The prime function of thrombin is the cleavage of fibrinogen to generate fibrin monomers, which form an insoluble gel by cross-linking, thereby initiating thrombus formation. UFH and LMWH have thrombolytic properties, i.e. they induce dissolution of the thrombus formed.

Contrary to UFH and LMWH, some synthetic oligosaccharides, especially oligosaccharides described in EP 84,999 and US 5,378,829, highly selectively inhibit factor Xa via antithrombin III (ATIII) but do not have any activity on thrombin. However, notwithstanding the absence of any capacity to inhibit thrombin or to promote thrombolysis, it appeared that those oligosaccharides inhibit thrombus formation, e.g. as occurring in extracorporeal blood circuits.

Thus, surprisingly, it has now been found that a synthetic oligosaccharide which is a selective inhibitor of factor Xa, acting via antithrombin III, is useful for preventing blood clotting in patients with an extracorporeal blood circuit.

The use of the oligosaccharide according to this invention results in effective and safe inhibition of blood clotting, e.g. in patients undergoing haemodialysis, without increased bleeding risks.

A preferred oligosaccharide for the use according to this invention is the pentasaccharide with the formula methyl O-(2-deoxy-2-sulphoamino-6-O-sulpho- α -D-glucopyranosyl)-(1 \rightarrow 4)-O-(β -D-glucopyranosyl uronic acid)-(1 \rightarrow 4)-O-(2-deoxy-2-sulphoamino-3,6-di-O-sulpho- α -D-

IN THE CLAIMS:

- -- 11. A method for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment comprising administering 0.001 to 10 mg of methyl $O-(3,4-di-O-methyl-2,6-di-O-sulpho-\alpha-D-glucopyranosyl)-(1\rightarrow4)-O-(3-O-methyl-2-O-sulpho-<math>\beta$ -D-glucopyranosyl uronic acid)- $(1\rightarrow4)-O-(2,3,6-tri-O-sulpho-\alpha-D-glucopyranosyl)-(1\rightarrow4)-O-(3-O-methyl-2-O-sulpho-<math>\alpha$ -L-idopyranosyl uronic acid)- $(1\rightarrow4)-O-(3-O-methyl-2-O-sulpho-\alpha-L-idopyranosyl)$ uronic acid)- $(1\rightarrow4)-2,3,6-tri-O-sulpho-\alpha-D-glucopyranoside or a salt thereof per kg body weight of the patient. --$
- -- 12. A method for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment comprising administering 0.30 to 30 mg of methyl O- $(3,4-\text{di-O-methyl-2},6-\text{di-O-sulpho-}\alpha-\text{D-glucopyranosyl})-(1\rightarrow4)-\text{O-}(3-\text{O-methyl-2-O-sulpho-}\beta-\text{D-glucopyranosyl})$ uronic acid)- $(1\rightarrow4)$ -O- $(2,3,6-\text{tri-O-sulpho-}\alpha-\text{D-glucopyranosyl})-(1\rightarrow4)$ -O- $(3-\text{O-methyl-2-O-sulpho-}\alpha-\text{D-glucopyranosyl})$ uronic acid)- $(1\rightarrow4)$ -O- $(3-\text{O-methyl-2-O-sulpho-}\alpha-\text{D-glucopyranosyl})$ uronic acid)- $(1\rightarrow4)$ -2,3,6-tri-O-sulpho- α -D-glucopyranoside or a salt thereof. --

- -- 13. The method of claim 11, comprising administering a dodecasodium salt thereof. --
- -- 14. The method of claim 12, comprising administering a dodecasodium salt thereof. --
- -- 15. A method for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment comprising administering 0.001 to 10 mg of methyl $O-(2,3,4-\text{tri-}O-\text{methyl-}6-O-\text{sulpho-}\alpha-D-\text{glucopyranosyl})-(1\rightarrow4)-O-(2,3-\text{di-}O-\text{methyl-}\beta-D-\text{glucopyranosyl})$ uronic acid)- $(1\rightarrow4)-O-(2,3,6-\text{tri-}O-\text{sulpho-}\alpha-D-\text{glucopyranosyl})-(1\rightarrow4)-O-(2,3-\text{di-}O-\text{methyl-}\alpha-L-\text{idopyranosyl})$ uronic acid)- $(1\rightarrow4)-O-(2,3-\text{di-}O-\text{methyl-}\alpha-L-\text{idopyranosyl})$ uronic acid)- $(1\rightarrow4)-O-(2,3-\text{di-}O-\text{methyl-}\alpha-D-\text{glucopyranosyl})$ uronic acid)- $(1\rightarrow4)-O-(2,3,6-\text{tri-}O-\text{sulpho-}\alpha-D-\text{glucopyranoside})$ or a salt thereof per kg body weight of the patient. --
- -- 16. A method for preventing clotting in an extracorporeal blood circuit of a patient undergoing extracorporeal blood treatment comprising administering 0.30 to 30 mg of a methyl $O-(2,3,4-\text{tri-}O-\text{methyl-}6-O-\text{sulpho-}\alpha-D-\text{glucopyranosyl})-(1\rightarrow4)-O-(2,3-\text{di-}O-\text{methyl-}\beta-D-\text{glucopyranosyl})$ uronic acid)- $(1\rightarrow4)-O-(2,3,6-\text{tri-}O-\text{sulpho-}\alpha-D-\text{glucopyranosyl})-(1\rightarrow4)-O-(2,3-\text{di-}O-\text{methyl-}\alpha-L-\text{idopyranosyl})$ uronic acid)- $(1\rightarrow4)-O-(2,3-\text{di-}O-\text{methyl-}\alpha-L-\text{idopyranosyl})$ uronic acid)- $(1\rightarrow4)-O-(2,3-\text{di-}O-\text{methyl-}\alpha-L-\text{idopyranosyl})$ uronic acid)- $(1\rightarrow4)-O-(2,3-\text{di-}O-\text{methyl-}\alpha-L-\text{idopyranosyl})$ uronic acid)- $(1\rightarrow4)-O-(2,3-\text{di-}O-\text{methyl-}\alpha-D-\text{glucopyranoside})$ or a salt thereof. --

- -- 17. The method of claim 15, comprising administering a nonasodium salt thereof. --
- -- 18. The method of claim 16, comprising administering a nonasodium salt thereof. --

REMARKS

Claims 2-10 are cancelled and new claims 11-18 are added. Claims 11-18 are presented for examination.

It is believed that claims 11-18 recite a patentable improvement in the art. Favorable action is solicited. In the event any fees are required with this paper, please charge our Deposit Account No. 02-2334.

Respectfully submitted,

William M. Blackstone Attorney for Applicants Registration No. 29,772

Attorney Docket No. O/97277 US/D1 Akzo Nobel Patent Department 1300 Piccard Drive, Suite 206 Rockville, Maryland 20850-4373

Tel: (301) 948-7400 Fax: (301) 948-9751

WMB:lcf 11STIEKEMA-DIVPREAMENDMENT